NCT00077350: A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 48 | US | triapine, 3-AP, OCX-191, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, laboratory biomarker analysis | National Cancer Institute (NCI) | Recurrent Non-small Cell Lung Cancer | 04/05 | | | |
NCT00077415: 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 31 | RoW | gemcitabine hydrochloride, triapine | Cancer Therapeutics Research Group, National Cancer Institute (NCI) | Lung Cancer | 01/08 | 02/08 | | |
